Article

An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease

Emory University, Atlanta, Georgia, United States
Clinical Neurophysiology (Impact Factor: 2.98). 11/2007; 118(10):2189-94. DOI: 10.1016/j.clinph.2007.07.010
Source: PubMed

ABSTRACT Major depression is a common concomitant of chronic central nervous system disorders, notably Parkinson's disease (PD). Repetitive transcranial magnetic stimulation (rTMS) has been investigated as a potential treatment for depression in PD and for the movement disorder of PD, but comprehensive testing in multiple areas of performance has seldom been carried out within a single study. We studied the effect of left dorsolateral prefrontal rTMS on several different functional domains.
Fourteen PD patients with treatment-resistant depression entered an open, 10-day inpatient study of 10-Hz rTMS, undergoing extensive psychiatric, neuropsychological, and motor testing from baseline to 6 weeks after treatment. Motor testing included a defined "off" state.
rTMS was well tolerated. Highly significant improvement in depression scores was seen 3 days and 3-6 weeks after treatment. Improvement was also found in anxiety, movement scores (especially in the off state), and some neuropsychological measures. We found no evidence of increased risk from rTMS in this population.
Further controlled trials of rTMS in PD appear worthwhile, and should include a defined "off" state.
TMS may be beneficial for depressed PD patients in multiple functional domains.

0 Followers
 · 
121 Views
 · 
0 Downloads
  • Source
    • "frequency rTMS improves more than low frequency or sham in MMSE,GDS,IADL Cotelli et al. (2011) [38] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Repetitive transcranial magnetic stimulation (rTMS) represents a promising tool for studying and influencing cognition in people with neurodegenerative diseases. This procedure is noninvasive and painless, and it does not require the use of anesthesia or pharmacological substances. In this systematic critical review we report outcomes from research focused on behavioral cognitive effects induced by rTMS in patients with Alzheimer's disease (AD), Parkinson's disease (PD), and mild cognitive impairment (MCI) preceding AD. There are still major limitations to rTMS use, such as a poor understanding of its after-effects and inter-individual variability in their magnitude, discrepancies in stimulation protocols and study designs, varied selection of the specific stimulated areas and control procedures, and neuropsychological methods for assessment of after-effects; hence, the results of the present research can only be considered preliminary. The future directions are discussed.
    Journal of the neurological sciences 02/2014; 339(1-2). DOI:10.1016/j.jns.2014.01.037 · 2.26 Impact Factor
  • Source
    • "We found five studies using rTMS for the treatment of depression in PD. Two were randomized clinical trials (RCTs) and three were open trials (64-66). Fregni et al. (67) evaluated 42 patients using high-frequency rTMS over the DLPFC. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with clinical diseases often present psychiatric conditions whose pharmacological treatment is hampered due to hazardous interactions with the clinical treatment and/or disease. This is particularly relevant for major depressive disorder, the most common psychiatric disorder in the general hospital. In this context, nonpharmacological interventions could be useful therapies; and, among those, noninvasive brain stimulation (NIBS) might be an interesting option. The main methods of NIBS are repetitive transcranial magnetic stimulation (rTMS), which was recently approved as a nonresearch treatment for some psychiatric conditions, and transcranial direct current stimulation (tDCS), a technique that is currently limited to research scenarios but has shown promising results. Therefore, our aim was to review the main medical conditions associated with high depression rates, the main obstacles for depression treatment, and whether these therapies could be a useful intervention for such conditions. We found that depression is an important and prevalent comorbidity in a variety of diseases such as epilepsy, stroke, Parkinson's disease, myocardial infarction, cancer, and in other conditions such as pregnancy and in patients without enteral access. We found that treatment of depression is often suboptimal within the above contexts and that rTMS and tDCS therapies have been insufficiently appraised. We discuss whether rTMS and tDCS could have a significant impact in treating depression that develops within a clinical context, considering its unique characteristics such as the absence of pharmacological interactions, the use of a nonenteral route, and as an augmentation therapy for antidepressants.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 10/2013; 46(10):815-908. DOI:10.1590/1414-431X20133115 · 1.08 Impact Factor
  • Source
    • "The transient magnetic field then causes an electrical current in neurons or axons in the brain (Ni and Chen, 2009). At the moment, TMS has been widely used in neurophysiological studies, and its effect is being investigated in the treatment of neurological and psychiatric diseases, including Parkinson's disease, schizophrenia, and depression (Sachdev et al., 2002; Epstein et al., 2007; Zaman et al., 2008; González-García et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transcranial magnetic stimulation (TMS) is a procedure that uses magnetic fields to stimulate or inhibit nerve cells in the brain noninvasively. TMS induces an electromagnetic current in the underlying cortical neurons. Varying frequencies and intensities of TMS increase or decrease excitability in the cortical area directly targeted. It has been suggested that TMS has potential in the treatment of some neurological disorders such as Parkinson's disease, stroke, and depression. Initial case reports and open label trials reported by several groups support the use of TMS in pain treatment. In the present study, we evaluated the effect of TMS on the nociceptive threshold in the rat. The parameters used were a frequency of 60 Hz and an intensity of 2 and 6 mT for 2 hr twice per day. After 5 days of TMS treatment, rats were evaluated for mechanical, chemical, and cold stimulation. We observed a significant reduction in the nociceptive threshold in TMS-treated rats but not in sham-treated rats in all behavioral tests evaluated. When TMS treatment was stopped, a slow recovery to normal mechanic threshold was observed. Interestingly, i.c.v. MK-801 or CNQX administration reverted the TMS-induced pronociception. The results suggest that high-frequency TMS can alter the nociceptive threshold and produce allodynia in the rats; results suggest the involvement of NMDA and AMPA/KA receptors on TMS-induced allodynia in the rat.
    Journal of Neuroscience Research 05/2012; 90(5):1085-95. DOI:10.1002/jnr.22785 · 2.73 Impact Factor
Show more

Preview

Download
0 Downloads
Available from